Vismodegib is a Hh-pathway inhibitor acting at the level of Smoothened (Smo), and using the optimized treatment scheme from Eberl et al. (2018) we tested whether established de novo HFs would persist or would diminish as the BCC-tumor-growth area does. The gene discussed is SMO; the disease is Hand-foot syndrome.